isis 2503
Nucleic acidexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 1999 (NCT00004193)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Transforming protein p21/H-Ras-1INHIBITOR
HRAS inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 2503
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00006467 | Phase 2 | Feb 1, 2001 | Mayo Clinic, National Cancer Institute (NCI) |
| NCT00005594 | Phase 2 | Jul 1, 2000 | Ionis Pharmaceuticals, Inc., National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00004193 | Phase 2 | Jan 1, 1999 | National Cancer Institute (NCI), University of Alabama, Birmingham |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 3 | 1 | 1 | 1999 |
| University of Alabama, Birmingham | Academic/Hospital | 2 | 2 | 1 | 1999 |
| Ionis Pharmaceuticals, Inc. | For profit | 1 | 0 | 1 | 2000 |
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2001 |
4 organizations
Page 1 / 1